GBIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 730-735

  Coller, Barry S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; THROMBIN; TIROFIBAN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

BLEEDING; CONFERENCE PAPER; CORONARY ARTERY BYPASS SURGERY; DRUG EFFICACY; DRUG POTENCY; ISCHEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; RISK FACTORS; TREATMENT OUTCOME;

EID: 0030611288     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657620     Document Type: Conference Paper

References (42)

1. Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 1994;31:301-11.
2. Weiss HJ, Turitto VT, Baumgartner HR. The role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium: studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest 1986;78:1072-82.
3. Coller BS. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Art Dis 1992;3:1016-29.
4. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
5. Topol EJ, Califf RM, Weismann HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
6. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
7. Abciximab package insert. 1995
8. Jordan RE, Wagner CL, Mascelli M, et al. Horton MD MA, editors. Adhesion Receptors as Therapeutic Targets. Boca Raton: CRC Press, Inc. 1996; 15, Preclinical development of c7E3 Fab; a mouse/human chimeric monclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. p. 281-305.
9. Simoons ML, de Boer MJ, van den Brand MJ, van Mittenburg AJ, Hoorntje JC, Hegndrickx GR, van der Wicken LR, de Bono D, Rutsch W, Schaible TF, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina.. Circulation 1994;89:596-603.
10. Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 1993;4:729-37.
11. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab Patients with Glanzmann thrombasthenia in Israel. Blood 1991;77:75-83.
12. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993;5:864-8.
13. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88:907-14.
14. Wencel-Drake J. Plasma membrane GPIIb/IIIa. Evidence for a cycling receptor pool. Am J Pathol 1990;36:61-70.
15. Pike NB, Lumley P. Uptake of a fibrinogen receptor antagonist by human platelets appears dependent upon GPIIb/IIIa. [Abstract] Thromb and Haemostas 1995;73:1195
16. Morgenstern E, Ruf A, Patscheke H. Transport of anti-glycoprotein IIb/IIIa-antibodies into the alpha-granules of unstimulated human blood platelets. Thromb and Haemostas 1992;67:121-5.
17. Peerschke EI. Adhesive protein expression on thrombin-stimulated platelets: time-dependent modulation of anti-fibrinogen, -fibronectin, and -von Willebrand factor antibody binding. Blood 1992;79:948-53.
18. Gralnick HR, Williams SB, McKeown L, Shafer B, Connaghan GD, Hansmann K, Vail M, Magruder L. Endogenous platelet fibrinogen: its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen. Br J Haematol 1992;80:347-57.
19. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-71.
20. Wagner CL, Cunningham MR, Wyand MS, et al. Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys. [Abstract] Thromb Haemostas 1995;73:1313.
21. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low dose weight-adjusted heparin in patients treated with the platelet GPIIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. [In Press] Am J Cardiol 1997
22. Ward SR, Lincoff AM, Miller DP, et al. Clinical outcome is improved at 30 days regardless of pre-treatment clinical and angiographic risk in patients receiving abciximab for angioplasty: results from the EPILOG study. [Abstract] Circulation 1996;94:(Suppl.)I-198.
23. Aguirre FA, Talley DJ, Ferguson JJ, III, Tcheng J, Kleiman NS, Montague EA, Booth JE, Lincoff AM. Efficacy of abciximab, despite patient weight, using lower heparin dosing during percutaneous coronary intervention. Circulation 1996;94(Suppl.):I-198.
24. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy. (Submitted)
25. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-6.
26. Christopoulos CG, Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody. Br J Haematol 1994;87:650-2.
27. Bednar B, Bednar RA, Cook JJ, Booag DM, Chang CT, Gaul SL, McQueney PA, Egbertson MS, Hartman GD, Holahan MA, et al. Drug-dependent antibodies against GPIIb/IIIa induce thrombocytopenia. Circulation 1996;94:I-99.
28. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325-38.
29. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced, thrombin generation by the mouse/human chimeric 7E3 anibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-74.
30. Coller BS. Augmentation of thrombolysis with antiplatelet drugs. Overview. Coron Art Dis 1996;6:911-4.
31. Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 1994;83:1006-16.
32. Carr ME, Jr., Carr SL, Hantgan RR, Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost 1995; 73:499-505.
33. Schwartz SM, Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol 1993;21 Suppl 1:S31-49.
34. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994;90:1908-18.
35. Schwartz SM. Serum-derived growth factor is thrombin? J Clin Invest 1993;91:4.
36. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-62.
37. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet GPIIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. [In Press] Circulation 1997
38. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking avb3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19:125-34.
39. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994;90:2203-6.
40. van der Zee R, Passeri J, Barry JJ, et al. A neutralizing antibody to the alpha v beta 3 integrin reduces neointimal thickening in a balloon-injured rabbit iliac artery. [Abstract] Circulation 1996;98:(Suppl.)I-257.
41. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. Am J Cardiol 1994;74:1166-70.
42. Coller BS, Lang D, Scudder LE. A rapid and simple platelet function assay to assess GPIIb/IIIa receptor blockade. [In Press] Circulation 1997